Orthocell has released the replay of its July investor webinar, in which Chair John Van Der Wielen, CEO and Managing Director Paul Anderson, CFO Jim Piper and VP U.S. Sales John Walker set out the strategy behind the Company’s record FY2026 results and the momentum building in its U.S. commercialisation of Remplir™.
Insights from the webinar include:
- A foundation-first approach to the U.S. market.
Rather than pursuing rapid, broad-based expansion, Orthocell is building depth with a targeted group of centres of excellence first in a strategy designed to establish long-term, sustainable growth and preserve the Company’s future distribution options.
- A growing approval pipeline underpinning future growth.
Orthocell’s VAC (Value Analysis Committee) submissions represent hospital-level approvals working their way through the system, with each one unlocking a new institution for ongoing Remplir use once cleared.
- Momentum building beneath the surface.
U.S. procedural volume grew approximately 20% quarter-on-quarter, reflecting deepening adoption among existing surgeons and hospitals as much as new customer growth.
- Word-of-mouth driving distributor demand.
Prospective U.S. distributors are increasingly approaching Orthocell directly, prompted by results being shared between existing distributors across different markets.
- Manufacturing ownership underpinning margin. With manufacturing, intellectual property and 14 international product approvals held in-house, Orthocell retains its full production margin, representing a significant advantage as U.S. volumes scale.
- Expanding global and clinical footprint.
New distributor appointments in Thailand, Canada and Hong Kong, continued humanitarian deployment of Remplir in Ukraine, and growing surgeon adoption in radical prostatectomy nerve repair all point to a broadening base for future growth, alongside the newly commenced U.S. regulatory pathway for Orthocell’s tendon repair product.